Search research articles
Contact Us
Filters
Showing results (521-530 of 962) with videos related to
Page
of 97
Sort By:
European Heart Journal
|
June 3, 2017
Visit-to-visit variability of blood pressure and cardiovascular outcomes in patients with stable coronary heart disease. Insights from the STABILITY trial
Emmanuelle Vidal-Petiot, Amanda Stebbins, Karen Chiswell, et al.
Circulation
|
January 13, 2021
Clinical Efficacy and Safety of Alirocumab After Acute Coronary Syndrome According to Achieved Level of Low-Density Lipoprotein Cholesterol: A Propensity Score-Matched Analysis of the ODYSSEY OUTCOMES Trial
Gregory G Schwartz, Philippe Gabriel Steg, Deepak L Bhatt, et al.
Clinical Cardiology
|
May 27, 2021
The effect of sex on the efficacy and safety of dual antithrombotic therapy with dabigatran versus triple therapy with warfarin after PCI in patients with atrial fibrillation (a RE-DUAL PCI subgroup analysis and comparison to other dual antithrombotic therapy trials)
David S Eccleston, Joseph M Kim, Jurien M Ten Berg, et al.
The New England Journal of Medicine
|
August 28, 2018
Rivaroxaban for Thromboprophylaxis after Hospitalization for Medical Illness
Alex C Spyropoulos, Walter Ageno, Gregory W Albers, et al.
JACC. Cardiovascular Interventions
|
December 7, 2019
Switching of Oral Anticoagulation Therapy After PCI in Patients With Atrial Fibrillation: The RE-DUAL PCI Trial Subanalysis
Jurrien M Ten Berg, Anne de Veer, Jonas Oldgren, et al.
Circulation
|
January 15, 2016
Efficacy and Safety of Cangrelor in Women Versus Men During Percutaneous Coronary Intervention: Insights From the Cangrelor versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition (CHAMPION PHOENIX) Trial
Michelle L O'Donoghue, Deepak L Bhatt, Gregg W Stone, et al.
Journal of the American Heart Association
|
November 5, 2017
Double-Dose Versus Standard-Dose Clopidogrel According to Smoking Status Among Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention
Matthias Bossard, Christopher B Granger, Jean-Francois Tanguay, et al.
Circulation
|
November 1, 2017
Frequency, Predictors, and Impact of Combined Antiplatelet Therapy on Venous Thromboembolism in Patients With Symptomatic Atherosclerosis
Ilaria Cavallari, David A Morrow, Mark A Creager, et al.
Journal of the American College of Cardiology
|
June 27, 2020
Post-Discharge Prophylaxis With Rivaroxaban Reduces Fatal and Major Thromboembolic Events in Medically Ill Patients
Alex C Spyropoulos, Walter Ageno, Gregory W Albers, et al.
Circulation
|
August 3, 2016
Consistent Reduction in Periprocedural Myocardial Infarction With Cangrelor as Assessed by Multiple Definitions: Findings From CHAMPION PHOENIX (Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition)
Matthew A Cavender, Deepak L Bhatt, Gregg W Stone, et al.
Page
of 97
Search research articles
Search
Showing results (521-530 of 962) with videos related to
Sort By:
Page
of 97
European Heart Journal
|
June 3, 2017
Visit-to-visit variability of blood pressure and cardiovascular outcomes in patients with stable coronary heart disease. Insights from the STABILITY trial
Emmanuelle Vidal-Petiot, Amanda Stebbins, Karen Chiswell, et al.
Circulation
|
January 13, 2021
Clinical Efficacy and Safety of Alirocumab After Acute Coronary Syndrome According to Achieved Level of Low-Density Lipoprotein Cholesterol: A Propensity Score-Matched Analysis of the ODYSSEY OUTCOMES Trial
Gregory G Schwartz, Philippe Gabriel Steg, Deepak L Bhatt, et al.
Clinical Cardiology
|
May 27, 2021
The effect of sex on the efficacy and safety of dual antithrombotic therapy with dabigatran versus triple therapy with warfarin after PCI in patients with atrial fibrillation (a RE-DUAL PCI subgroup analysis and comparison to other dual antithrombotic therapy trials)
David S Eccleston, Joseph M Kim, Jurien M Ten Berg, et al.
The New England Journal of Medicine
|
August 28, 2018
Rivaroxaban for Thromboprophylaxis after Hospitalization for Medical Illness
Alex C Spyropoulos, Walter Ageno, Gregory W Albers, et al.
JACC. Cardiovascular Interventions
|
December 7, 2019
Switching of Oral Anticoagulation Therapy After PCI in Patients With Atrial Fibrillation: The RE-DUAL PCI Trial Subanalysis
Jurrien M Ten Berg, Anne de Veer, Jonas Oldgren, et al.
Circulation
|
January 15, 2016
Efficacy and Safety of Cangrelor in Women Versus Men During Percutaneous Coronary Intervention: Insights From the Cangrelor versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition (CHAMPION PHOENIX) Trial
Michelle L O'Donoghue, Deepak L Bhatt, Gregg W Stone, et al.
Journal of the American Heart Association
|
November 5, 2017
Double-Dose Versus Standard-Dose Clopidogrel According to Smoking Status Among Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention
Matthias Bossard, Christopher B Granger, Jean-Francois Tanguay, et al.
Circulation
|
November 1, 2017
Frequency, Predictors, and Impact of Combined Antiplatelet Therapy on Venous Thromboembolism in Patients With Symptomatic Atherosclerosis
Ilaria Cavallari, David A Morrow, Mark A Creager, et al.
Journal of the American College of Cardiology
|
June 27, 2020
Post-Discharge Prophylaxis With Rivaroxaban Reduces Fatal and Major Thromboembolic Events in Medically Ill Patients
Alex C Spyropoulos, Walter Ageno, Gregory W Albers, et al.
Circulation
|
August 3, 2016
Consistent Reduction in Periprocedural Myocardial Infarction With Cangrelor as Assessed by Multiple Definitions: Findings From CHAMPION PHOENIX (Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition)
Matthew A Cavender, Deepak L Bhatt, Gregg W Stone, et al.
Page
of 97